Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer

Journal of Nuclear Medicine

Volumn 54, Issue 5, 2013, Pages 776-784

  Xavier, Catarina ^a   Vaneycken, Ilse ^a,b   D'Huyvetter, Matthias ^a   Heemskerk, Johannes ^b   Keyaerts, Marleen ^a,b   Vincke, Cécile ^a,c   Devoogdt, Nick ^a   Muyldermans, Serge ^a,c   Lahoutte, Tony ^a,b   Caveliers, Vicky ^a,b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

68Ga; HER2; iPET; Nanobodies; NOTA

Indexed keywords

1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID 2RS15D GA 68; 2 (4 ISOTHIOCYANATOBENZYL) 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID; ACETIC ACID DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NANOBODY; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; DRUG BINDING; DRUG DISTRIBUTION; DRUG SYNTHESIS; GOOD MANUFACTURING PRACTICE; IMAGING SOFTWARE; ISOTOPE LABELING; LIVER; MOUSE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

68GA; HER2; IPET; NANOBODIES; NOTA;

ADULT; ANIMALS; CELL LINE, TUMOR; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG STABILITY; FEMALE; GALLIUM RADIOISOTOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS; HUMANS; MICE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOMETRY; RATS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; SINGLE-DOMAIN ANTIBODIES;

EID: 84877102221     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.111021     Document Type: Article

References (32)

1. Mendelsohn J, Howley PM, Israel MA, Gray JW, Thompson CB. The Molecular Basis of Cancer. Philadelphia, PA: Saunders, Elsevier; 2008:160-161, 339, 425, 427-428, 575.
2. Hicks DG, Kulkarni S. HER2 1 breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol. 2008;129:263-273. (Pubitemid 352029317)
3. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des. 2008;14:2999-3019.
4. Oude Munnink TH, Nagengast WB, Brouwers AH, et al. Molecular imaging of breast cancer. Breast. 2009;18(suppl 3):S66-S73.
5. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24:2276-2282. (Pubitemid 46630657)
6. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-592.
7. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004;22:701-706. (Pubitemid 38702826)
8. Adams GP, Schier R, Marshall K, et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 1998;58:485-490. (Pubitemid 28087411)
9. Vaneycken I, Devoogdt N, Van Gassen N, et al. Preclinical screening of anti-HER2 Nanobodies for molecular imaging of breast cancer. FASEB J. 2011;25:2433-2446.
10. Olafsen T, Sirk SJ, Olma S, Shen CK, Wu AM. ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumour Biol. 2012;33:669-677.
11. HER2:2395 in a mouse model for ovarian cancer. J Nucl Med. 2012;53:146-153.
12. 68Ga-labeled affibody molecules. J Nucl Med. 2010;51:892-897.
13. 111In-labelled analogue. Eur J Nucl Med Mol Imaging. 2010;37:1356-1367.
14. 68Ga for PET imaging of HER2 expression. J Nucl Med. 2009;50:1492-1499.
15. Zahnd C, Kawe M, Stumpp MT, et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res. 2010;70:1595-1605.
16. 99mTc-labeled anti-EGFR Nanobodies in mice, using pinhole SPECT/microCT. J Nucl Med. 2008;49:788-795.
17. 68Ga via a novel bifunctional desferal chelate for immuno-PET. Eur J Nucl Med Mol Imaging. 2011;38:753-763.
18. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363:446-448. (Pubitemid 23179389)
19. Muyldermans S. Single domain camel antibodies: current status. J Biotechnol. 2001;74:277-302. (Pubitemid 34179619)
20. Arnau J, Lauritzen C, Petersen GE, Pedersen J. Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins. Protein Expr Purif. 2006;48:1-13. (Pubitemid 43782626)
21. Shimp RL Jr, Martin LB, Zhang Y, et al. Production and characterization of clinical grade Escherichia coli derived Plasmodium falciparum 42kDa merozoite surface protein 1 (MSP142) in the absence of an affinity tag. Protein Expr Purif. 2006;50:58-67. (Pubitemid 44755034)
22. 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imaging. 2008;3:67-77.
23. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010;110:2858-2902.
24. 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 2009;50:974-981.
25. 68Ga-DOTA-Affibody molecule for in vivo assessment of HER2/neu expression with PET. Eur J Nucl Med Mol Imaging. 2011;38:1967-1976.
26. Gainkam LO, Caveliers V, Devoogdt N, et al. Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific Nanobody in mice. Contrast Media Mol Imaging. 2011;6:85-92.
27. Vegt E, de Jong M, Wetzels JF, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51:1049-1058.
28. 177Lu-Nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators. Contrast Media Mol Imaging. 2012;7:254-264.
29. 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009;50:1828-1836.
30. 18F-FDG PET/CT examinations. J Nucl Med. 2005;46:608-613.
31. Broisat A, Hernot S, Toczek J, et al. Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions. Circ Res. 2012;110:927-937.
32. Movahedi K, Schoonooghe S, Laoui D, et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. 2012;72:4165-4177.